Evidence map›Paper›PMID 40932632›Full record

ArticlePituitary2025

Silent growth hormone pituitary adenomas: a single-center study.

Tongxin Xiao, Xinxin Mao, Xueqing Zheng, Ran Li, Linjie Wang, Yong Yao, Kan Deng, Fengying Gong, Hui Pan, Lin Lu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tongxin XiaoKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Xinxin MaoDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xueqing ZhengKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Ran LiKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Linjie WangKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Yong YaoDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Kan DengDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Fengying GongKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Hui PanKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Lin LuKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China.
Huijuan ZhuKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China. zhuhj@pumch.cn.ORCID http://orcid.org/0000-0001-5172-6870
Lian DuanKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Medical College, Peking Union Medical College Hospital, Dongdan campus No.1 Shuaifuyuan Wangfujing Dongcheng District, 100730, Beijing, China. duanlian@pumch.cn.ORCID http://orcid.org/0000-0002-4213-474X

Funding

the National High-Level Hospital Clinical Resear 2022-PUMCH-A-155the National High-Level Hospital Clinical Research Funding 2022-PUMCH-B-016
6 · The paper itself

Abstract

purposeTo characterize the clinicopathological features and metabolic profiles of silent growth hormone pituitary adenomas (SGH-PAs).

methodsThe single-center retrospective study identified SGH-PAs from 1387 surgically treated non-functioning PAs at Peking Union Medical College Hospital (2019-2023). Controls included 407 consecutive cases with non-functioning gonadotropin pituitary adenomas (NFG-PAs) and 90 age and gender-matched acromegaly patients. Baseline and postoperative hormonal assessments, pituitary imaging features, pathological classification, metabolic comorbidity, and follow-up outcome were collected and analyzed.

results45 cases of SGH-PA (3.2%) were identified from 1387 non-functioning PAs. The pathological subtypes included 18 (40%) acidophil stem cell adenomas, 11(24%) immature PIT1-lineage tumors, 5 sparsely granulated GH tumors, 5 mammosomatotroph tumors, 4 mature plurihormonal PIT1 lineage tumors, and 2 plurihormonal pituitary tumors. Compared to controls, SGH-PAs showed modestly elevated proliferation (median Ki-67 3% vs. 2% in both acromegaly [p = 0.002] and NFG-PAs [p = 0.011]) without outstanding increases in tumor invasiveness (Knosp 3-4: 20-30% across groups) at baseline or 2-year recurrence. Baseline metabolic comorbidities paralleled NFG-PA profiles for hypertension (22%) and diabetes (8.9%), with reduced dyslipidemia prevalence (17.8% vs. 33.4%, p = 0.049). No case of SGH-PAs transforming into acromegaly was confirmed during 77 person-years of follow-up.

conclusionsSGH-PAs represent approximately 3% of nonfunctioning PAs undergoing surgery. Multiple anterior pituitary hormones are commonly co-expressed. These tumors may be more proliferative, but the baseline aggressiveness in radiology and short-term recurrence rates are similar.

Indexed as

AdenomaGrowth Hormone-Secreting Pituitary AdenomaPituitary NeoplasmsAcromegalyAdultAgedFemaleHuman Growth HormoneHumansMaleMiddle AgedRetrospective StudiesHuman Growth HormoneComorbidityGrowth hormonePituitary adenomaSilent pituitary tumors

Identifiers

PMID40932632
PMCPMC12426092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.